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Abstract 
Chronic pruritus is a major and distressing symptom common to several conditions that 
arises from a complex dialogue between skin cells and neurons, sustained by mediators, 
such as cytokines, neurotransmitters, endothelial adhesion molecules, angiogenic factors 
and other biomolecules. Pruritus is a common symptom in cutaneous T cell lymphoma 
(CTCL), mastocytosis and psoriasis. The response to similar therapies is often different 
between the diseases and between different clinical stages of the same condition, 
strengthening the need to clarify the underlying pathways, cells and mediators involved in 
pruritus in these diseases.  
The goal of this study was to clarify the mechanisms underlying pruritus in CTCL, 
mastocytosis and psoriasis patients. For that, we measured the levels of different cytokines 
(IL-8, IL-31 and IL-33), neuromediators (serotonin), endothelial adhesion molecules (E-
selectin) and angiogenic factors (vascular endothelial growth factor; VEGF) in these 
patients. For each disease under study, the correlation of the several biomarkers with 
itching score and severity of the disease was studied. 
We found that CTCL patients presented increased levels of IL-31 and E-selectin, 
especially patients with Sezary Syndrome (SS); moreover, E-selectin correlated with 
pruritus in SS. In Mycosis Fungoides (MF) serotonin presented a tendency for higher levels. 
Pruritus correlated with tryptase levels in mastocytosis. Finally, although we found elevated 
levels of IL-8, E-selectin, VEGF and C–reactive protein (CRP) in psoriasis, they did not 
correlate with pruritus.  
In summary, our data suggest that serotonin and tryptase are important biomarkers in 
mastocytosis; the high levels of E-selectin and CRP in the severer forms of psoriasis 
suggest that these parameters are potential biomarkers of psoriasis severity; in patients 
with SS, E-selectin and IL-31 appear to be important in itchy pathways; in MF patients the 
increase in serotonin seems to be more important in the mechanisms underlying pruritus. 
However, more studies are needed to clarify itch mechanisms in the three diseases. 
Our data strengthens the hypothesis that different mechanisms underlie the genesis of 
itch, explaining the different therapeutic responses to common treatments, and proposes 
some potential therapeutic targets for the treatment of itch in CTCL, mastocytosis and 
psoriasis patients. 
 
Key-words:  Pruritus; Cutaneous T-cell Lymphoma; Mastocytosis; Psoriasis; 
Inflammation 
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Resumo 
O prurido crónico é um sintoma importante e comum a várias doenças, que resulta de 
um diálogo complexo entre células da pele e neurónios, sustentado por mediadores, como 
citocinas, neurotransmissores, moléculas de adesão vascular, fatores angiogénicos e 
outras biomoléculas. O prurido é um sintoma comum no linfoma cutâneo de céulas T 
(CTCL), na mastocitose e na psoríase. A resposta a terapias similares frequentemente 
difere entre as várias doenças e entre diferentes estadios clínicos da mesma doença, 
reforçando a necessidade de esclarecer quais as vias de sinalização, células e mediadores 
subjacentes ao prurido nestas doenças.  
O objetivo deste estudo foi clarificar os mecanismos envolvidos na génese do prurido 
no CTCL, na mastocitose e na psoríase. Para isso, medimos os níveis de diferentes 
citocinas (IL-8, IL-31 e IL-33), neurotransmissores (serotonina), moléculas de adesão 
vascular (E-seletina) e fatores angiogénicos (fator de crescimento endotelial; VEGF), 
nestes doentes. Para cada doença, as correlações entre os diferentes biomarcadores com 
o nível de prurido e a severidade da doença foram estudadas.  
Os nossos resultados mostram que os doentes com CTCL apresentam níveis 
aumentados de IL-31 e E-seletina, particularmente os doentes com síndrome de Sezary; 
para além disso, neste doentes, os níveis de E-seletina correlacionaram-se com o prurido. 
Na mycosis fungoides, a serotonina apresentou valores tendencialmente mais elevados. 
Na mastocitose, o prurido relacionou-se com os níveis de triptase. Finalmente, embora 
tenhamos encontrado níveis aumentados de IL-8, E-seletina, VEGF e proteína C-reativa 
(CRP) nos doentes de psoríase, estes não se relacionaram com o prurido.  
Em suma, os nossos resultados sugerem que a serotonina e a triptase são importantes 
biomarcadores na mastocitose; os níveis elevados de E-seletina e de CRP, nas formas 
mais severas de psoríase, sugerem que estes parâmetros são potenciais biomarcadores 
da severidade desta doença; nos doentes com síndrome de Sezary, a E-seletina e a IL-31 
parecem ser importantes nas vias pruriceptivas; nos doentes com mycosis fungoides, a 
serotonina parece ser um importante biomarcador. Contudo, são necessários mais estudos 
para identificar os mecanismos envolvidos no prurido destas três doenças. 
Os nossos dados suportam a hipótese de que diferentes mecanismos participam na 
génese do prurido, explicando as diferentes respostas à terapêutica, e propõem potenciais 
alvos terapêuticos para o tratamento do prurido nos doentes com CTCL, mastocitose e 
psoríase. 
 
Palavras-chave: Prurido, Linfoma Cutâneo de células T, Mastocitose; Psoríase; 
Inflamação
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Introduction 
Chronic pruritus is a major and distressing symptom common to several conditions that 
can significantly impair the patients’ health-related quality of life (QoL). One of the first 
scientists that studied itch was von Frey, proposing an intensity hypothesis for itch and 
claiming that itch was a milder form of pain. Years later, Lewis reported that pain had two 
presentations: the “first pain”, pricking, sharp, superficial and localized; and the “second 
pain”, the burning pain, more diffuse and deep, following the first pain (1). Similarly, Graham 
et al. also reported that itch caused by the plant spicule cowhage (the itch powder) had two 
components mediated by different nerve fibres: the pricking itch was mediated by 
myelinated A-δ fibres that lead to the first pain, and the burning itch was mediated by 
unmyelinated C-fibres that lead to the second pain (2). They also found that itchy skin had 
a lower threshold for pain, that itch could be abolished by painful stimuli, and that areas of 
hyperalgesia were insensitive to itch. Pain and itch thus appeared to be processed by the 
same neuronal circuits (1); nowadays, it is known that both pain and itch are transmitted by 
the anterolateral system (3).  
The pattern theory, one of the two most reliable theories concerning pruriceptive sensory 
processing in the nervous system, postulates that stimuli activate different kinds of 
nociceptors and spinal cord neurons and that the sum of the neuronal activity determines 
the sensation felt. According to this theory, the pattern of activation determines that itch is 
felt upon pruriceptive stimuli, and not pain or non-noxious touch (4). However, evidences 
suggest a distinct neuronal pathway for pain and itch: for instance, certain kinds of pain 
don’t turn into itch when the stimuli get weaker; itch can be very intense and bothersome 
without turning into pain; opioids decrease pain but increase itch and while pain elicits a 
withdrawal behaviour, itch leads to scratching. Pain can be felt in virtually all the body, from 
the surface to muscles and inner organs, while itch can only be felt in the skin and mucosal 
surfaces (5). Neuroimaging studies revealed that different areas of the brain are activated 
during itch and pain (6). These observations are in agreement with the second and most 
accepted theory for itch: the specificity theory, that claims a specific pathway of neurons 
along the central and peripheral nervous systems, responsible for the translation and 
transmission of pruriceptive information (4).  
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 Neuroanatomy and physiology of itch 
Itch is somatosensory, as pain, temperature, and others. Sensory stimuli are processed 
by the sensory system, which has an ascending (afferent) pathway in the nervous system. 
Itch perception begins in skin receptors and mucosal surfaces. This sensory information is 
converted to neuronal signals that travel through the spinal cord into higher areas of the 
brain, namely the thalamus and the somatic sensory cortex. The system of neurons that 
transmit itch, pain, temperature and, in a less extension, touch, is the anterolateral or 
spinothalamic system (3, 7). 
 Primary afferent fibres  
Pruritogens activate the free (or bare) nerve endings (which comprise the sensory 
portion) of primary afferent fibres, also called dorsal root ganglion neurons (3). The 
branches of dorsal root ganglion neurons collect in the dorsal root.  
Free nerve endings (FNE) of primary afferent fibres have membrane receptor channel 
complexes that convert the received stimuli into electric signals. These membrane receptor 
channels are different, regarding the type of substances to which that fibre is sensitive (8). 
FNE of C-fibres and A-δ fibres subserve different sensory modalities (9). The most common 
type of C-fibres, the polymodal C-fibres, respond to painful, mechanical and heat stimuli, 
but they are not, or are very weakly, activated by histamine. Histamine-responsive afferents 
are a subtype of unmyelinated C-fibres that possess wide enervation territories, are 
mechanically unresponsive and have slow conduction velocities (10, 11), termed mechano-
insensitive histamine-positive C-units (CMiHis+). Although considered itch-specific, these 
afferent fibres are responsive to heat (10), as well as to some algogens (substances that 
cause pain) (11). This response to noxious stimuli of CMiHis+ units may explain the 
abolishment of itch by pain and, thus, the scratching reflex in an itchy area (11). 
Cowhage also triggers itch by activating mechanically sensitive C-fibres (4), indicating 
that itch is mediated by more than one type of C-afferent fibres. Additionally, myelinated A-
δ fibres seem to have an important role in non-histaminergic cowhage-mediated itch (12). 
 Spinal cord  
Electrical signals flow through the axons into the cell bodies of primary afferent fibres,  
synapsing on second-order neurons located in the dorsal column nucleus of the dorsal horn 
of the spinal cord (4). Pruriception ascends the brain from the spinal cord via the 
spinothalamic tract (STT). Although stimuli caused by both histamine and cowhage activate 
STT neurons, they never activate the same cell (13), indicating that cowhage and histamine 
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activate different types of afferent fibres and of STT neurons, despite sharing a common 
pathway, supporting the hypothesis of more than one mechanism for itch.  
 Brain  
The axons of dorsal column nucleus neurons reach the contralateral thalamus. From 
here, axons project to the somatic sensory cortex of the parietal lobe in the cerebral 
hemispheres (3).  
 Pain and itch inhibition in the nervous system 
The STT has two projections, one of which is to the periaqueductal grey matter that 
surrounds the cerebral aqueduct in the midbrain. This is a key region in pain modulation, 
as it is from here that raises a descending pain inhibitory system. The periaqueductal grey 
matter receives emotional information from higher structures of the brain. Then, excitatory 
neurons project to nuclei in the medulla and then the dorsal horn of the spinal cord, using 
serotonin to directly inhibit ascending neurons that transmit painful information and activate 
inhibitory interneurons (3).  
Pain seems to act as a counter-stimulus for itch, as scratching relieves this symptom. 
Studies have proven that painful heat, scratching (14, 15) and cold (16) relieved 
histaminergic itch, the latter being mediated by the activation of A-δ fibres. 
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 Mediators of itch 
Pruriceptive information is translated and conducted by molecular signals via 
inflammatory mediators, neurotransmitters and both endogenous and exogenous 
substances. Pruritogens activate receptors in FNE, exciting neurons to release 
neurotransmitters to communicate the information to next-level neurons in the STT.  
 Amines 
Histamine has been the most studied pruritogen and is considered the classic itch 
mediator. Like serotonin, histamine is a biogenic amine. After intradermal injection or 
intrinsic release of histamine from activated mast cells and basophils, a local reaction 
occurs. Histamine causes vasodilation of local arterioles and an erythema spreads several 
centimetres around the area where it occurs, originating a flare. Vasodilation also allows 
plasma extravasation from the blood vessels, with subsequent oedema or wheal formation 
in the skin (17). This sequence of events (flare, spread of the flare and wheal) is known as 
the “triple response”. Histaminergic itch is triggered by stimulation of histamine receptors in 
FNE. A molecular signalling pathway results in the depolarization of the nerve fibres via 
activation of voltage-dependent sodium channels (18).  
Serotonin is a neurotransmitter synthesized from the aminoacid tryptophan. Intradermal 
injection of serotonin causes itch, although to a less extent than histamine (11). Serotonin-
mediated itch is processed by the same molecular signalling cascade as histamine (18), 
although it appears to be independent of it. In fact, serotonin induced non-histaminergic itch 
in the lesioned skin of atopic dermatitis patients (19) and an antagonist of serotonin receptor 
did not relieve pruritus induced by histamine in healthy subjects (20). A study reported that 
serotonin levels were increased in patients with mastocytosis, although they did not 
correlate with pruritus (21). Serotonin reuptake inhibitors improved the condition of patients 
with malignant disease (22) and also with psoriasis (23). It is believed that serotonin is also 
implicated in the pruritus of cutaneous T-cell lymphoma (CTCL) (1). 
 Neuropeptides 
Substance P (SP) is a neurotransmitter highly important in the communication between 
primary afferents and the central nervous system. SP is released upon activation of FNE, 
which induce mast cells to release histamine with the subsequent triple response and itch 
(24, 25). Degranulated mast cells also release other inflammatory mediators, such as 
prostaglandins, leukotrienes (26) and cytokines (27), leading to a further release of SP by 
FNE and activation of mast cells (26, 28), keratinocytes and endothelial immune cells (8, 
28). It thus appears that SP is not a pruritogen by itself, but, instead, acts as a mediator for 
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histaminergic itch. SP has also a role in inflammatory and systemic disease, as experiments 
with a SP receptor antagonist relieved itch in patients with chronic pruritus of various origins 
(29) and in patients with pruritus due to CTCL unresponsive to other treatments (30).  
 Cytokines 
Cytokines are immunomodulators released mainly by leukocytes and some of them 
seem to have an important role in pruritus in different conditions. Interleukin (IL)-2, IL-31 
and IL-33 have been associated with pruritus in some diseases, such as CTCL, 
mastocytosis and psoriasis. 
IL-2, a cytokine involved in the proliferation and maturation of T-cells, causes itch in 
healthy subjects and atopic dermatitis patients (31); the dermis of psoriatic patients with 
pruritus presented increased levels of IL-2, compared to non-pruritic psoriatic skin (32); 
plasma levels of IL-2 were also increased in haemodialysis patients with uremic pruritus 
(33); an IL-2 antagonist relieved pruritus in a Sezary syndrome case study (34). 
IL-8 is produced by antigen presenting cells (APCs), keratinocytes, mast cells and other 
cell types. This chemotactic cytokine, known to be increased in psoriasis and to correlate 
with its severity (35), induces neutrophil mobilization, transmigration and degranulation. IL-
8 mRNA expression may be enhanced by histamine and tumour necrosis factor (TNF)-α via 
stimulation of histamine-4 receptors in keratinocytes, which are involved in pruritus and skin 
inflammation (36). IL-8 is also involved in the pathogenesis of malignancies, such as 
mastocytosis (37) and CTCL (38). However, Vaa et al. did not find a correlation between 
IL-8 levels and pruritus in primary myelofibrosis patients (39). 
IL-31 is a cytokine synthesized by a variety of cells, including lymphocytes and mast cells 
(40) that has been proposed as a potential mediator in the genesis of pruritus in several 
diseases. Increased levels of IL-31 have been found in dermatologic diseases, such as 
atopic dermatitis (41), as well as in proliferative disorders like mastocytosis (42), CTCL (43) 
and polycythaemia vera (PV) (44). Although some data showed that IL-31 correlates with 
pruritus in CTCL (45, 46), other reported otherwise (47). Furthermore, IL-31 receptors have 
been reported in dorsal root ganglion neurons, indicating that IL-31 may directly activate 
sensory neurons (41) and cause itch, without further interference of mediators. 
IL-33, known to induce Th2 cytokine responses, seems to be involved in association with 
IL-31 in the pathogenesis of skin side effects, including itch, observed in a patient treated 
with epidermal growth factor receptor tyrosine kinase inhibitors (48). 
6 
 Arachidonic acid metabolites 
Prostaglandins and leukotrienes are arachidonic acid metabolites synthesized via the 
cyclooxygenase and lipoxygenase pathways, respectively. These molecules seem to 
mediate itch rather than being direct pruritogens. In a study with healthy individuals, 
prostaglandin E2 enhanced histamine-induced pruritus (49). Leukotriene B4 concentration 
was increased in the affected skin of patients with atopic dermatitis and psoriasis (50). 
 Other mediators 
E-selectin (also termed endothelial-leukocyte adhesion molecule 1; ELAM-1) is an 
important adhesion molecule of the inflammatory process, recruiting leukocytes into the site 
of injury. It was demonstrated that homing of T lymphocytes from Sezary syndrome patients 
in dermal microvessels in mouse ear skin was mediated by E-selectin and other adhesion 
molecules (51). Also, E-selectin had an two-fold increase in psoriatic skin with pruritus 
compared to non-pruritic lesioned skin (32). E-selectin also appears to be important in the 
process of angiogenesis (52). 
Vascular endothelial growth factor (VEGF) is a pro-angiogenic molecule that has been 
implicated in the pathogenesis of inflammatory and systemic diseases. VEGF is increased 
in psoriasis patients (35), is produced by mast cell infiltrates in the bone marrow of 
mastocytosis patients (53) and by malignant CTCL cells (54). VEGF seems to have a 
particular role in pruritus, as increased levels correlated with disease activity in prurigo 
simplex, a chronic inflammatory skin condition; moreover, pruritus improved in a patient 
after treatment with bevacizumab, a monoclonal VEGF antibody (55).  
 Mucunain 
Known as itch powder, cowhage are the spicules of the plant Mucuna pruriens. Cowhage 
invokes itch of higher intensity than that produced by electric skin stimulation or intradermal 
injection of histamine and is mediated by the protease mucunain (56). As mentioned before, 
histamine and cowhage activate different C primary afferents and STT neurons (13), what 
clearly defines separate pathways for itch perception.  
7 
 Diseases associated with itch 
Pruritus is classified as acute, when the patient complains of itch for less than six weeks, 
or as chronic pruritus, a debilitating symptom that accompanies many dermatological and 
systemic diseases. The International Forum for the Study of Itch (IFSI) proposed in 2007 a 
clinical and aetiological classifications for itch (57). For clinical purposes, group I is defined 
as pruritus on primary inflamed skin, including dermatological disorders like psoriasis or 
atopic dermatitis; group II - pruritus on primary non-diseased, non-inflamed skin disorders, 
including systemic, neurological or psychiatric diseases in which pruritus is present but skin 
lesions are absent. However, there are systemic disorders that present with skin lesions 
and, on the other hand, there are also dermatological diseases in which the skin appears 
healthy. Therefore, a close examination by a dermatologist is of significant importance in all 
cases of pruritus. Finally, group III includes diseases that present skin changes, due to 
intense scratching, frequently observed in patients with chronic itch for several years. The 
underlying diseases in which pruritus is a symptom are also separated by categories - 
Category I: dermatological diseases; Category II: Systemic diseases, including diseases of 
pregnancy and drug-induced pruritus; Category III: Neurological; Category IV: 
Psychiatric/psychosomatic diseases; Category V: Mixed (pruritus that is due to more than 
one disease); and, Category VI: Other (no underlying cause can be found). 
 Dermatological diseases 
Chronic, non-infectious skin conditions such as atopic dermatitis, eczema or psoriasis, 
are non-curable diseases that have implications in the patients’ QoL and self-esteem. These 
dermatologic diseases are often associated with pruritus (58), being itch one of the most 
reported symptom in dermatology consults.  
3.1.1 Psoriasis 
Psoriasis is an inflammatory chronic recurrent skin condition that affects approximately 
2% of the global population, accounting for nearly 125 million people worldwide (59). The 
word “psoriasis” derives from the Greek word psora, which means “itch”. Psoriasis is 
identified by its clinical and histological features and is known to affect patients self-esteem 
and QoL, leading to professional and personal limitations (59). Also, most psoriasis patients 
(67-92%) have complains of pruritus, sometimes occasional, other times moderate to 
severe and often associated with depression (60, 61). 
Psoriasis, characterized by abnormal proliferation of keratinocytes and vascular 
alterations, is triggered by genetic and non-genetic factors, such as infection, inflammation, 
stress, skin injury and drugs (62). Sun exposure appears to influence the geographic 
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distribution of this disease, as the prevalence of psoriasis increases with distance from the 
equator (59, 63). Populations from the Artic appear to have a prevalence of psoriasis up to 
12%, whereas it is practically non-existent in South America and Asia. Incidence appears 
to be higher in Europe than in the United States and increases with age (63). Children are 
less affected than adults. Psoriasis is classified according to the onset of the disease, as 
type I (early-onset) psoriasis, when the first peak occurs before the age of 40 (75% of all 
cases), and as type II psoriasis (late-onset), with the first manifestation occurring between 
50-60 years of age (59, 63). The disease occurs equally in both genders.  
Several genes have been implicated in the predisposition to this skin disease (59, 64). 
Psoriasis has been associated with certain human leukocyte antigen (HLA)-types such as 
HLA-Cw6, HLA-B13, HLA-B17, HLABw57, HLA-DR4 and HLA-DR7 (62), and those with 
HLA-Cw6 seem to have a 10-fold higher risk to develop a more severe disease (65). 
3.1.1.1 Pathogenesis 
Antigenic stimulation of skin immune cells, namely Langerhans cells, dendritic cells and 
other APCs, triggers an immune response with production of antimicrobial peptides and 
cytokines. Actually, APCs are capable of activating other immune cells, resulting in the 
recruitment of T-cells, neutrophils, mast cells and other inflammatory cells to the affected 
area (66, 67), through the release and expression of TNF-α, IL-8 and other inflammatory 
cytokines, and the expression of ligands to E-selectin and other adhesion molecules (59). 
If the epithelial barrier is lesioned, activated keratinocytes will synthesize structural and 
barrier proteins, in order to repair the injury and regain homeostatic balance. APCs 
communicate with T-cells, activating them to produce cytokines and other inflammatory 
mediators. Langerhans cells are also capable of travelling to lymph nodes, further 
stimulating more T-lymphocytes (66). Dermal T-cells are CD4+ T-helper (Th) cells and 
epidermal lymphocytes are CD8+ cytotoxic T cells (59). Dermal Th cells acquire an 
inflammatory phenotype, with clonal expansion of Th1/Th17 cells, leading to an enhanced 
production of interferon-gamma (IFN-γ), TNF-α, IL-1, IL-2, IL-6, IL-12, IL-17, IL-22 and IL-
23 (59, 66). This cytokine pool allows for macrophage and dendritic cells-mediated 
keratinocyte proliferation and inflammatory cell infiltration seen in histologic samples of 
lesioned psoriatic skin, sustaining the whole process.   
Mast cells produce, among others, VEGF and IL-8, increasing the permeability of 
surrounding blood vessels and helping in the recruitment of innate and adaptive immune 
cells (68). Neutrophils are a major player in the pathogenesis of psoriasis, helping in the 
recruitment and activation of T-cells and in the proliferation of keratinocytes (69). 
Keratinocytes produce chemotactic mediators, such as IL-6 and IL-8 that increase the 
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immune infiltrate in the skin (70), and VEGF, which leads to the increased vascularization 
of the tissue (71).  
This milieu of inflammatory cytokines is not localized only in lesioned skin. In fact, 
psoriasis patients have increased circulating levels of inflammatory cytokines (35). This 
chronic immunoinflammatory process contributes to the higher predisposition of psoriasis 
patients to co-morbidities, such as cardiovascular disease (72), metabolic disorders, 
gastrointestinal disease, diseases of the nervous system and cancer (59). 
3.1.1.2 Clinical manifestations 
Psoriasis can present in various clinical forms, according to the type and localization of 
lesions. The most common clinical form of psoriasis is chronic plaque psoriasis or psoriasis 
vulgaris. It presents with red plaques (due to intense local neovascularization) with silver or 
white scales (due to keratinocyte hyperplasia) that are absent in non-lesioned skin (59).  
3.1.1.3 Severity and Treatment 
The severity of psoriasis is often evaluated by the Psoriasis Area and Severity Index 
(PASI) score, which is performed by the physician. It combines the evaluation of four body 
areas: head and neck, upper limbs, trunk and lower limbs. To assess affected body surface 
area, the proportion of skin affected in each area is given by a numerical score. Within each 
area, the severity of the lesions is measured by three signs, erythema, thickness/induration, 
and desquamation/scaling (73). A PASI score below 10 defines psoriasis as mild, between 
10 and 20 as moderate, and above 20 as severe.   
Given the clinical presentation and the associated co-morbidities, psoriatic patients have 
a significant impairment in their QoL; complaints of stigmatization, depression and low self-
esteem are common; periods of higher stress (74) are usually linked to exacerbation of skin 
lesions, further contributing to diminish the self-esteem of the patients (59).  
The Dermatology Life Quality Index (DLQI) is a 10-items questionnaire, aimed to 
evaluate the QoL related with skin diseases. Its subscales are: symptoms and feelings, daily 
activities, leisure, work and school, personal relationships and treatment (59). The total 
DLQI score is calculated by summing the scores of the 10 questions; the maximum score 
is 30 and the minimum is 0. The DLQI score banding proposes: 0-1 means “no effect on 
QoL”; 2-5, “small effect”; 6-10, “moderate effect”; 11-20, “very large effect”; 21-30, 
“extremely large effect”. A total DLQI higher than 10 represents a skin disease with a very 
large effect on patients’ QoL. Psoriasis patients with enhanced PASI values present, 
usually, higher DLQI scores (75, 76). 
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The choice of psoriasis therapy depends on several factors, such as disease severity, 
skin type, response to previous treatments, effect on patient QoL, and clinical history. 
Topical therapy is used for milder or limited forms of psoriasis, and may be used in 
combination with other therapies. Phototherapy, photochemotherapy, systemic and 
biological agents are used for moderate and severe forms of psoriasis. Systemic therapy 
includes drugs, such as methotrexate, cyclosporine and systemic retinoids (59). Biological 
drugs comprises TNF inhibitors (etanercept, adalimumab, infliximab), ustekinumab, that 
targets the p40 subunit of IL-12 and IL-23, and the agents that target IL-17 (e.g. 
secukinumab and ixekizumab).  
3.1.1.4 Itch in Psoriasis 
Pruritus is a common symptom in psoriasis patients; 70-98% of psoriasis patients suffer 
from mild to severe itch (60, 61, 77-80). It is not consensual whether pruritus correlates with 
the PASI score: some studies report a significant positive correlation (75, 79, 81, 82), in 
opposition to others (32, 60, 77, 78, 80). Stress enhances pruritus (77, 79, 82), further 
aggravating QoL in psoriasis patients. 
Although the mechanisms involved in pruritus in psoriasis are not well understood, it is 
believed that the increase in nerve endings, induced by nerve growth factors, and the 
associated inflammation induced by neuropeptides, may decrease the threshold for 
sensibility to pruritic stimuli in affected skin (32, 79, 83). Some studies have showed that 
pruritus is not only felt in lesioned skin, but also in apparently healthy skin areas (60, 79, 
81), suggesting a systemic mechanism for itch in psoriasis, in addition to a local pathway. 
It was reported that IL-2 levels were increased in pruritic psoriasis lesions, compared to 
non-pruritic lesioned skin, although IL-8 levels were similar (32). Concerning the possible 
role of IL-31 in psoriatic pruritus, some authors reported increased levels in psoriasis 
patients (84), while others reported otherwise (85). Sonkoly and colleagues found no 
differences in IL-31 levels between pruritic and non-pruritic psoriatic skin (41), but Narbutt 
et al. observed that both IL-31 and pruritus decreased after treatment with narrow-band 
ultraviolet light B (84); this reduction in pruritus, however, may be due to skin improvement 
and not IL-31 decrease per se. Indeed, Szepietowski et al. reported that itch diminished 
when skin lesions were cleared (81). Other mediators such as serotonin (23) and E-selectin 
(32) may also have a role in pruritus associated with psoriasis. 
There is no specific treatment for pruritus in psoriasis. Usually, pruritus diminishes when 
skin condition improves. 
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 Haematological malignancies 
Pruritus has been associated with haematological disorders for decades, and is one of 
the symptoms that raises suspicion for malignancy when cutaneous lesions are absent (86). 
The term “paraneoplastic itch” is often employed when pruritus occurs in cancer patients; it 
is a rare symptom in most types of cancer, however it is frequently found in patients with 
blood malignancies (87), namely in PV, Hodgkin’s lymphoma, CTCL, mastocytosis, and 
others. 
3.2.1 Cutaneous T-Cell Lymphoma (CTCL) 
Primary cutaneous lymphomas are a rare and heterogeneous group of non-Hodgkin’s 
lymphomas, in which antigenic-stimulated malignant B and T lymphocytes with skin tropism 
proliferate and cause skin lesions.  
CTCL is the most common form of primary cutaneous lymphomas. The majority of CTCL 
are malignant diseases of mature Th cells, including the variants Mycosis Fungoides (MF) 
and Sezary Syndrome (SS). MF/SS have an indolent course and are epidermotrophic 
disorders (88), often mimicking benign skin conditions, such as psoriasis or eczema (89). 
In fact, initial skin lesions are both clinically and histologically non-specific. Years or even 
decades may pass between appearance of skin lesions and the final and correct diagnosis 
(88, 90). MF is a milder form of the disease that, as it progresses, the malignant clone in 
both skin and circulation increases, leading to severe skin involvement and to secondary 
complications observed in SS patients. The indolent variants of CTCL progress from 
clinically and histologically non-specific skin lesions (premycotic) to an erythematous or 
eczematoid stage, which may be accompanied by severe itching. The next stage, the 
infiltrative plaque stage, is characterized by indurated discrete papules, oval or round in 
shape. The tumour stage presents with ulcerative mass lesions in both previously injured 
and healthy skin (88).  
Classic MF progresses slowly and presents with well-defined pruritic erythematous skin 
patches in sun-protected areas. These lesions may evolve to infiltrative plaques and 
tumours. Histologically, the skin presents with a band-like lymphocytic infiltrate, variable 
number of inflammatory cells, clusters of malignant cells and, occasionally, apoptotic 
keratinocytes. Tumour lesions have deeper dermal infiltration and diminished 
epidermotropism. Folliculotropic MF is the most common MF subtype, presenting with 
severe pruritus, skin plaques, cysts and lesions; alopecia and scaring may occur. Pagetoid 
reticulosis is an indolent form of MF with localized scaling patches on the extremities. Skin 
histology reveals prominent epidermal hyperplasia. Granulomatous MF presents a more 
rapid disease progression and poor prognosis. Clinically, it resembles classic MF and may 
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present with different histopathologic patterns (89). MF tumour cells may undergo 
transformation, from small atypical lymphocytes to a large cell variant (89). These large 
atypical cells are also observed in Pagetoid reticulosis and are positive for CD30 marker 
(91).  
MF and SS may also present as erythrodermic CTCL, with mild and generalized 
exfoliative erythroderma, which causes electrolyte imbalances, hypothermia, eyelid 
changes and alopecia. These erythrodermic CTCL often resemble other dermatologic 
diseases, such as infections, psoriasis or eczema, and are usually considered as a 
progression of the disease without blood involvement (89).  SS, the leukemic form of CTCL, 
is more aggressive than MF, presenting Sezary cells, atypical, skin-homing malignant CD4+ 
lymphocytes, with a highly convoluted nucleus, condensed heterochromatin at the periphery 
and abnormal cytogenetics, in the skin and peripheral blood (88). Clinically, besides 
erythroderma, SS presents severe and disabling pruritus and, in some cases, 
lymphadenopathy. 
CTCL is more frequent in the elderly black male (55-60 years of age; 2:1 male to female 
ratio) (89, 92), with an annual incidence of 1:100,000 (93). It is believed that CTCL arises 
from a combination of environmental (particularly infections) and genetic factors. Exposure 
to toxic chemicals (88) and infection by Staphylococcus aureus, Epstein-Barr virus or 
cytomegalovirus may have a role in the triggering of MF/SS (89). HLA-B8, HLA-Aw31 and 
HLA-Aw32 may be also involved. First degree relatives of CTCL patients have higher risk 
of suffering from the disease as well, suggesting a genetic predisposition (88). 
MF/SS patients have also an increased risk of developing secondary malignant diseases 
(89), probably as a consequence of the invasion of virtually all organs by the malignant T 
clone in advanced stages (88). The most common cause of death is infection (50%), due to 
the permanent disruption of the skin barrier and impaired immunological responses (88). 
3.2.1.1 Pathogenesis 
A chronic antigenic exposure and stimulation of APCs (particularly dendritic cells) leads 
to an inflammatory response, with release of chemotactic products for both innate and 
adaptive immune cells, including T lymphocytes. APCs are also able to travel to lymph 
nodes, leading to the expansion of antigenic-specific effector and memory T-cells that enter 
the blood stream and the affected skin areas via adhesion molecules, such as E-selectin, 
further increasing skin homing of T-cells (91). A disturbance in this process may lead to a 
clonal proliferation of a malignant Th lymphocyte. As the disease progresses, there is a 
switch in the type of response. In the early stages, there is a dominance of the Th1 cytokine 
profile, with the production of IL-2 and IL-12. In advanced stages, a switch to a Th2 cytokine 
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profile allows the disease to escape the antitumor response (91) and leads to increased 
immunossupression and susceptibility to infection, with increased production of IL-4, IL-5, 
IL-10, IL-13, eosinophilia and high levels of immunoglobulin (Ig)E (89). Defects in the 
expression of the genes Fas and p53 have also been reported, leading to the inhibition of 
cellular apoptosis (91). The antigenic presentation by APCs, loaded with apoptotic material 
from CTCL cells, leads to the proliferation of T regulatory cells, with the expression of FoxP3 
and the immunosuppressive cytokine IL-10, further contributing to an immune-incompetent 
state (94). 
Although usually associated with the expansion of CD3+CD4+ T lymphocytes and mature 
memory T-cells (CD45RO+), MF may present increased levels of CD8+ T cells, particularly 
in early skin lesions. The malignant T lymphocytes have an aberrant downregulation of 
CD2, CD5 and CD7 markers, and the latter may be associated with disease progression 
(89). 
3.2.1.2 Staging and Treatment 
For staging of MF/SS, a tumour-node-metastasis-blood (TNMB) staging system is used 
(Table 1). This staging is dependent on the assessment of skin and lymph node 
involvement, haematopoietic and metabolic studies, identification and quantification of 
Sezary cells in blood by morphologic and/or cytometric analysis, and by imagiology in case 
of lymph node involvement (91). The clinical staging takes into account the TNMB 
classification system and is also defined as in Table 1. 
In the cases of early stage MF, in which only the skin is affected and has a favourable 
prognosis, skin directed therapies such as topical corticosteroids, topical retinoids and 
phototherapy, are the first line treatment (95). In advanced stages of MF/SS, the treatment 
is often refractory and the prognosis is unfavourable. Combined topical and systemic 
therapy, using retinoids, IFN, extracorporeal photopheresis and chemotherapy, are used to 
reduce tumour burden, delay disease progression and improve QoL of the patient (95). 
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Table 1. Tumour-node-metastasis-blood staging and clinical staging in cutaneous T cell 
lymphoma 
TNMB staging 
T (skin) N (lymph node) M (metastasis) B (blood) 
T1: Limited 
patch/plaque (<10% 
body surface area) 
N0: Clinically 
uninvolved 
M0: No visceral 
involvement 
B0: No circulating 
atypical (Sezary) cells 
T2: Generalized 
patch/plaque 
(≥ 10% body surface 
area) 
N1: Clinically 
abnormal, 
histologically 
uninvolved 
M1: Visceral 
involvement 
B1: Circulating atypical 
(Sezary) cells 
T3: Tumours N2: Clinically 
uninvolved, 
histologically involved 
  
T4: Generalized 
erythroderma 
N3: Clinically 
abnormal, 
histologically involved 
  
Clinical staging 
IA IB IIA IIB IIIA IIIB IVA IVB 
T1 T2 T1-2 T3 T4 T4 T1-4 T1-4 
N0 N0 N1 N0-1 N0 N1 N2-3 N0-3 
M0 M0 M0 M0 M0 M0 M0 M1 
 
The tumour-node-metastasis-blood (TNMB) staging system takes into consideration the 
involvement and type of lesion in the skin (T), the involvement of the lymph nodes (N), the absence 
or presence of metastasis (M) and Sezary cells (B). 
The clinical staging takes into account the TNMB classification. 
Adapted from Kim et al. (2005) (91). 
 
3.2.1.3 Pruritus in CTCL 
In CTCL patients, pruritus is frequent, chronic, severe and, usually, the earliest, most 
bothersome symptom (96, 97). As in other haematological malignancies, it is often 
exacerbated by water and heat. It affects adversely patients’ QoL, interfering with sleep, 
causing low self-esteem and, ultimately, significant physical and mental morbidity (90). Itch 
is particularly severe in the advanced CTCL variants, folliculotropic and erythrodermic MF, 
and SS. 
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The ethiology of itch in CTCL is unknown. Mast cells have a role in the skin 
manifestations of MF, especially in the advanced stage (98). As some mast cell mediators 
are recognised pruritogens, molecules like histamine might be involved in the pathogenesis 
of pruritus in CTCL. However, pruritic CTCL patients are often unresponsive to 
antihistamines (99). It has been recently proposed that itch is a direct result of the Th2 
response environment and intense local skin inflammation. Thus, a significant role for 
cytokines has emerged and IL-31 seems to be a promising mediator of itch in CTCL. IL-31 
is produced by Th2 cells, particularly by the malignant T-cell population in MF/SS (46). Its 
levels correlate with disease severity (43) and resolution of pruritus was associated with the 
decrease in IL-31 levels (45, 46). A study by Malek and colleagues did not find a relation 
between pruritus and IL-31 levels in early stage disease (47), probably due to the 
predominant Th1 environment in this stage of the disease. 
Nevertheless, other mechanisms might be involved. It was reported that an antagonist 
of a SP receptor improved pruritus and QoL in patients with erythrodermic CTCL (30); 
gabapentin, an anticonvulsant, and mirtazapine, an antidepressant, were successful in 
managing pruritus in advanced MF/SS (100).  
The choice of the treatment for pruritus depends of the stage and severity of CTCL, and 
of the patient’s clinical history. Management of pruritus is often achieved by treating the 
underlying disease. Thus, topical emollients and phototherapy are of high value in 
managing itch in early stages of CTCL. The use of systemic therapy in advanced stages is 
also effective in relieving pruritus and increasing QoL in some of these patients (96).  
3.2.2 Mastocytosis 
Mast cells (MCs) are effector cells produced by proliferation and differentiation of 
haematopoietic stem cells that are involved in allergic and other systemic disorders, skin 
inflammation and cancer. MCs are activated by allergens, complement molecules, 
cytokines and neuropeptides, immunoglobulins, poison and physical stimuli during host 
defence and acute inflammatory processes (101, 102). Activated MCs release pre-formed 
molecules, such as histamine, serotonin, TNF and proteases, and also synthesize de novo 
leukotrienes, prostaglandins, cytokines (IL-1, IL-6, IL-8 and others) and VEGF (103), 
modulating immune responses and leading to multifunctional tissue responses. 
Mastocytosis is a heterogeneous group of clinical disorders characterized by 
accumulation and activation of aberrant tissue MCs in the skin, bone marrow and other 
organs. Mastocytosis is initially asymptomatic and may present a chronic indolent course 
or evolve into a highly aggressive disease with multisystem involvement. Mastocytosis can 
be confined to the skin, in cutaneous mastocytosis (CM), or may affect other organs, in the 
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case of systemic mastocytosis (SM). The clinical manifestations of mastocytosis come from 
MC-derived mediators and from the destructive infiltration of organs by MCs, although the 
formers seem to have a more preponderant role in the course of the disease (101).  
Mastocytosis is a rare disease, despite its increase in the last decades, probably due to 
better awareness and diagnosis. Epidemiology data is scarce; a recent Danish population-
based study found that the prevalence of mastocytosis was 0.89/100 000/year (104).  
Mastocytosis may present different clinical features and severity. CM affects only the 
skin and is more common in children, with the onset around 2 years of age. CM has a good 
prognosis and the signs and symptoms normally resolve at adolescence. In adults, 
cutaneous disease is commonly associated with SM (101). Macropapular CM/Urticaria 
pigmentosa (UP) is the most common type of CM, presenting with red brown macules and 
papules that induce erythema, wheal and pruritus when scratched. The lesions are 
symmetrical, with 1 cm of diameter. The life expectancy of UP patients is equal to the 
general population. 
In SM, defined as a MC disease involving at least one extra cutaneous organ, the most 
of the patients present a D816V mutation and aberrant expression of CD25 molecule (the 
α-chain of the IL-2 receptor) (101). The most common SM, indolent SM, has a favourable 
prognosis without decreased life expectancy or organ damage. This variant has a low MC 
burden in the bone marrow, with a low rate of MC proliferation. The symptoms are, 
therefore, largely associated with the release of inflammatory cytokines by MCs, such as 
TNF-α, IL-1β and IL-6 (101, 105). The symptoms are chronic or episodic and include facial 
flushing, pruritus, palpitations, nausea, anxiety and depression, among others (101). A very 
common complication is mastocytosis-associated osteopenia and osteoporosis, which is 
related to the intensity of MC mediator release (106). The indolent SM patients have also 
an increased risk of suffering from anaphylaxis episodes, compared with the general 
population (107). SM with associated clonal haematological non-mast cell lineage disease 
is an aggressive variant of SM, in which besides the increased proliferation of MCs, the 
patients also develop a myelodysplastic/myeloproliferative syndrome or acute myeloid 
leukaemia. The malignant clones, usually, have the D816V mutation along with other 
mutations. The prognostic is unfavourable, with a significant reduction in patients’ survival. 
The aggressive SM is the most severe form of SM, in which end-organ dysfunction is a 
direct consequence of MC infiltration of the bone marrow, gastrointestinal tract, liver, spleen 
and lymph nodes. As occurs in SM with associated clonal haematological non-mast cell 
lineage disease, aggressive SM has a poor prognosis and a short survival rate.  
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SM is more common in adults and CM more common in the paediatric population, in 
which regression is common and usually occurs in puberty (108). Most cases of 
mastocytosis appear spontaneously, but there are reports of familial cases (109). 
3.2.2.1 Pathogenesis 
The differentiation and maturation of MCs from haematopoietic stem cells is dependent 
on the activation of the transmembrane receptor tyrosine kinase (CD117; KIT) by stem cell 
factor (SCF). The KIT receptor is widely expressed on haematopoietic stem cells of both 
myeloid and lymphoid lineages and is downregulated in all mature lineages, except in MCs 
(105). Mastocytosis arises from mutations in the KIT gene. The gain-of-function point 
mutation of the KIT gene in which a valine is substituted by an aspartic acid in the catalytic 
domain of the protein (termed D816V mutation) is the most common and important 
mutation, although mutations in other codons of the KIT gene, and mutations in other genes 
may also occur. The D816V mutation allows for autophosphorilation of KIT in the absence 
of SCF, leading to an increase in growth, differentiation, survival and activation of MCs (101, 
102). This mutation also allows an increase of MCs proliferation via IgE receptor through 
common signal pathways, further enhancing the MC burden. 
3.2.2.2 Diagnosis and Treatment 
Mastocytosis is difficult to diagnose since its symptoms may be nonspecific and mild. 
Differential diagnosis implies the distinction of mastocytosis from other MC neoplasms and 
diseases in which there is MC activation. Despite being a rare disease, the presence of 
characteristic skin lesions and signs and symptoms that relate to MC mediator release, 
should raise the suspicion of mastocytosis. In children, a histological or genetic evidence, 
in addition to skin lesions defines CM. In adults with typical skin lesions, a bone marrow 
examination is necessary to rule out SM. The diagnosis of SM is based on skin lesions, 
assessment of serum tryptase levels (normal values <20 ng/mL; increased with MC 
proliferation and activation), histological studies and detection of the genetic mutation in 
MCs of an extra-cutaneous tissue (110). After diagnosis, imagiology techniques aid in the 
classification of disease variant and severity. 
There is no cure for mastocytosis. Disease treatment aims to improve patients’ QoL, 
which is severely impaired, by blocking production and release of inflammatory mediators 
by MCs. A first therapy approach is the treatment with histamine receptor antagonists, which 
control skin symptoms, tachycardia and abdominal pain, in patients with SM. A continued 
therapy with calcium and vitamin D is prescribed to patients with osteoporosis. Leukotriene 
antagonists are prescribed when histamine receptor antagonists are unsuccessful, and to 
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manage gastrointestinal and cutaneous complications in paediatric mastocytosis. Other 
drugs, such as systemic glucocorticoids, the monoclonal antibody omalizumab, 
phototherapy and cytoreductive drugs, proved to be effective in reducing skin and other 
symptoms in some patients (111). Additionally, patients are advised to avoid potential  
triggers of systemic mediator release, as occurs in the case of ingestion of spicy foods, 
insect bites, emotional stress, exercise practice, among others (101). 
3.2.2.3 Itch in mastocytosis 
Pruritus is the most common symptom reported by mastocytosis patients and appears 
to result from MC mediator release. 
Histamine seems to be an important mediator in the pruritus of mastocytosis, as 
histamine receptor antagonists are the first line of treatment for CM and are effective in the 
treatment of this symptom in some patients (111). However, other molecules may be also 
involved, such as IL-31, that is largely produced by MCs. Ishii et al. demonstrated that in 
myeloproliferative disorders, pruritus was significantly correlated with MC burden, 
decreased apoptosis and high IL-31 levels (44). Moreover, IL-31 serum levels were 
increased in mastocytosis patients and correlated with disease severity, but this 
enhancement was not associated with pruritus and other skin symptoms (42).  
In the early stages of a chronic allergic reaction, skin MCs rapidly produce IL-8, in order 
to recruit and activate granulocytes (112). Neutrophil chemotactic activity is also increased 
in mastocytosis patients with pruritus, as compared to non-pruritic patients (113). 
Human MCs are capable of producing and releasing serotonin and possess serotonin 
receptors in their surface (114). Serotonin levels follow a different pattern in mastocytosis 
patients, compared to healthy subjects, but no correlation was observed between serotonin 
and pruritus in these patients, regardless of the disease variant (21). 
The bone marrow of mastocytosis patients presents increased angiogenesis (53). 
Neoplastic cells from SM express both VEGF and VEGF receptors mRNA (115). However, 
Brockow et al. found that VEGF serum levels were not increased in mastocytosis patients, 
compared to atopic dermatitis patients or healthy subjects (116). 
Th2 immune responses may have an important role in mastocytosis. In fact, MCs are 
classically involved in inflammatory responses against helminthic infections, in which Th2-
derived cytokines enhance MC proliferation and activation (117). It was reported that IL-3, 
IL-4 and IL-10 downregulated protein and mRNA levels of KIT in MCs and other 
haematopoietic cells (118, 119), which, altogether, points to a strict regulation of MCs by 
Th2 mediators. However, Spínola et al. did not find increased circulating levels of basophils 
or Th2 lymphocytes in mastocytosis patients, in comparison with healthy subjects (120).  
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 Other systemic disorders 
Itch is a frequent symptom in liver disorders, particularly in those that affect the biliary 
tree. Cholestatic pruritus may occur in pregnant women, may be drug-induced (121, 122) 
or caused by viral infections (hepatitis B and C). The vast majority of Human 
Immunodeficiency Virus (HIV) patients complain of pruritus during some point in the course 
of the disease either due to the infection itself (123) or to a secondary condition, such as a 
dermatological disorder (124). 
 Neurological/Psychiatric disorders 
Neuropathic itch is present in various conditions of the nervous system and occurs 
without stimulation by a pruritogen. Itch has been reported in multiple sclerosis, spinal 
tumours, depression, and other dysfunctions of the central and peripheral nervous system 
(125).  
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 Evaluation of itch and treatment 
Itch is a highly underestimated condition. Indeed, despite the prevalence of itch in 
dermatologic disorders and in other pathologies, few studies address the prevalence of itch 
in European countries (1). Studies performed in Norway (126) and Germany (127) reported 
that chronic itch appears to be more frequent in adult women, with poor well-being (up to 
20% had depression). Surprisingly, near half of the patients complaining of high intensity 
pruritus that impaired their QoL did not seek for medical advice. More studies are necessary 
to assert the influence of these and other variables in the occurrence of itch. Probably, one 
of the reasons to the scarce epidemiology data, is that patients don’t seek a physician. This 
may be due to the organization of the healthcare system or it may be a cultural or 
educational aspect.  
In 2014, fifteen European countries united efforts to improve the assessment and 
treatment of chronic pruritus in dermatological care, by developing the European Network 
on Assessment of Severity and Burden of Pruritus (PruNet) (128). Their main goal was to 
evaluate several Patient-reported Outcome (PRO) tools used in the diagnosis of itch in 
adults, in order to unify criteria and pursue guidelines. The investigation of the intensity of 
pruritus and the impact of itch in the patient’s QoL were the most important tools to evaluate 
pruritus. Although it is not validated in most countries, the visual analogue scale (VAS) is 
the most used tool to assess the intensity of pruritus (128). It consists of a 10 cm line with 
a scale from 0 to 10 in which the patients cross the scale in the point that correlates with 
the intensity of their pruritus: the beginning of the scale (0 points) indicates no pruritus, and 
the end (10 points) of the scale, the most severe pruritus (129). Although VAS is a reliable 
tool to assess the intensity of pruritus, it has several limitations: it may be influenced by 
circadian variation and is not suitable for patients with motor or cognitive disorders that 
prevent them from either using a pen or understand the VAS (129). New tools on evaluating 
itch are being developed to overcome these difficulties and to assess the impact of itch in 
the patient’s QoL. One example is the ItchyQol, a pruritus-specific QoL questionnaire, that 
evaluates patients’ symptoms, functional limitations and emotions (130). 
Regarding treatment, patients often see their pruritus unrelieved or mildly attenuated by 
the drugs currently available. These drugs include histamine receptor antagonists, selective 
serotonin reuptake inhibitors, inhibitors of arachidonic acid pathways, SP inhibitors, and 
immunosuppressive drugs. In spite of the availability of these itch-specific treatments, 
patients with the same underlying disease may respond differently to the same treatment. 
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Aims  
Chronic pruritus is a major and distressing symptom common to several dermatological 
and haematological conditions. Pruritus arises from a complex dialogue between skin cells 
and neurons from both the peripheral and central nervous system. This dialogue appears 
to be sustained by mediators such as cytokines, growth factors, neurotransmitters and other 
molecules. Indeed, mechanisms underlying itch are complex and seem to involve, for the 
different diseases, different pathways, cells and mediators. 
 Pruritus is a common symptom in CTCL, mastocytosis and psoriasis, having a 
significant impairment in patients’ health-related QoL. The immune response seems to have 
a crucial role in these inflammatory conditions, raising the hypothesis that some cytokines 
and growth factors may be important for the inflammatory response and for pruritus. The 
response to similar therapeutic strategies to treat these pruritus-associated diseases is 
often different, strengthening the need to clarify the underlying mechanisms of pruritus in 
these skin diseases and to identify potential therapeutic targets. This study aims to clarify 
the pathways and mediators that may trigger pruritus in CTCL, mastocytosis and psoriasis 
patients, by evaluating different cytokines (IL-8, IL-31 and IL-33), neuromediators 
(serotonin), endothelial adhesion molecules (E-selectin) and angiogenic factors (VEGF). 
For each disease under study, the correlation of the several biomarkers with itching score 
and severity of the disease will be studied. By clarifying the mediators involved and by 
establishing their relationship with pruritus, we expect to contribute to a better knowledge 
on the mechanisms triggering pruritus, and to identify potential therapeutic targets.  
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Materials and Methods 
 Subjects  
The scientific and ethic committees of University Hospital of Coimbra (CHUC) and 
Hospital Santo António from Centro Hospitalar do Porto (CHP) approved this study. All 
patients and controls provided written informed consent.  
The control group included 33 apparently healthy volunteers (blood donors) with normal 
haematological and biochemical values. Adult psoriasis vulgaris patients (n=30), from 
CHUC and CHP had moderate to severe disease, according to the PASI score. Moderate 
psoriasis patients (n=16) presented a PASI score below 20, and a PASI score >20 was 
indicative of severe disease (n=14). None of the psoriasis patients received any treatment 
for at least one month prior to inclusion. CTCL patients (n=29) from CHP were adults, with 
either MF (n=17), SS (n=10) or unclassified CTCL (n=2). Adult mastocytosis patients (n=17) 
were from CHP.  
Patients and controls presenting other skin diseases, inflammatory or infectious diseases 
and liver or kidney diseases were excluded from the study. Controls and patients were not 
under any dietary restriction or therapy that could interfere with the results. 
Pruritus was auto-evaluated in CTCL and mastocytosis patients using a number scale 
(0-10) similar to VAS. In psoriasis patients, the pruritus felt in the preceding week was auto-
evaluated in a scale of 0 to 3. This evaluation is included in the first question of DLQI 
questionnaire (Annex 1) “Over the last week, how itchy, sore, painful or stinging has your 
skin been?”. 
 Sample collection 
Blood from nonfasted subjects was collected in order to obtain whole blood (EDTA as 
anticoagulant) and serum. None of the collected samples was icteric or haemolysed. Serum 
aliquots were stored at -80°C until analysis. 
 Analytical studies 
A complete blood count was performed using an automatic haematological counter 
(LH780, Coulter, California, USA). 
IL-8, IL-31 (BioLegend, California, USA), IL-33, VEGF, E-selectin, (eBioscience, 
California, USA), C-reactive protein (CRP; R&D Systems, Minneapolis, USA) and serotonin 
(Enzo Life Sciences, New York, USA)  were quantified in serum, using enzyme linked 
immunosorbent assays (ELISA), according to the manufacturer’s instructions. 
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In mastocytosis patients, serum tryptase levels were evaluated by a Fluoro Immuno 
Enzymatic Assay (ImmunoCap, ThermoFisher Scientific, Massachusetts, USA). Tryptase 
levels were considered elevated when above 20 ng/mL.  
 Statistical analysis 
All statistical analyses were performed in IBM SPSS Statistics 23 for Windows (IBM 
Corporation, New York, USA). A Kolmogorov-Smirnov (n>50) or Shapiro-Wilk (n<50) test 
was used to determine the distribution of the variables. Data is presented as median levels 
(interquartile range, IQR), as all variables follow a non-parametric distribution. To evaluate 
differences between groups, the Kruskal–Wallis H test was used and, when statistical 
significance was achieved, single comparisons (two groups) were made by using the Mann–
Whitney U test. Spearman’s rank correlation coefficient was used to evaluate relationships 
between sets of data. Adjustment of statistical differences for confounding factors was 
performed by analysis of covariance (ANCOVA). For that analysis, non-parametric data was 
transformed to parametric data, using the method described by Templeton (131).  
Graphical representations were made using GraphPad Prism 7.01 (GraphPad Software, 
Inc., California, USA).  
A P value <0.05 was considered statistically significant 
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Results 
Our results were analysed in two steps, firstly by comparing each group of patients with 
the control group and by comparing CTCL, mastocytosis and psoriasis patients. This was 
followed by a subanalysis, comparing the CTCL patients with MF with those presenting SS; 
comparisons between moderate and severe psoriasis patients were also performed.  
In Table 2, demographic and clinical data for controls and patients is presented. Patients 
and controls were not matched for age; in the case of mastocytosis patients, they were not 
matched for gender with controls. Thus, as previously referred, an adjustment for age and 
gender of the studied variables was made. All differences kept their significance after this 
adjustment.  
 
Table 2. Demographic and clinical data for controls and patients 
 
Control  
(n=33) 
CTCL  
(n=29) 
Mastocytosis  
(n=17) 
Psoriasis  
(n=30) 
Age (years) 58 (54-61) 66 (55-74) * 43 (36-58) ** ● 50 (31-57) *** ● 
Gender  
M (n/%) 22/66.7 15/51.7 5/29.4 * 13/43.3 
F (n/%) 11/33.3 14/48.3 12/70.6 * 17/56.7 
Pruritus (VAS) - 1 (0-9) 1 (0-2) - 
Pruritus  
(1st question DLQI)1 
- - - 2 (1-3) 
PASI - - - 18.9 (12.0-24.9) 
 
Pruritus was evaluated by a method analogous to the visual analogue scale (VAS) in cutaneous 
T-cell lymphoma (CTCL) and mastocytosis patients and by the first question of the dermatology life 
questionnaire index (DLQI) in psoriasis patients1.  
1 “Over the last week, how itchy, sore, painful or stinging has your skin been?” 
M, male; F, female; PASI, psoriasis area and severity index. 
*P vs control <0.05; **P vs control <0.01; ***P vs control ≤0.001; ● P vs lymphoma ≤0.001 
 
The total leucocyte, neutrophil, lymphocyte and monocyte counts of controls and patients 
are presented in Table 3. No significant changes were observed. 
 
Table 3. Haematological studies in control and patients 
 
Control  
(n=33) 
CTCL  
(n=29) 
Mastocytosis  
(n=17) 
Psoriasis  
(n=30) 
WBC (x109/L) 6.3 (5.4-7.9) 6.6 (5.7-8.0) 7.9 (5.6-9.1) 7.3 (6.0-8.1) 
Neutrophils (x109/L) - 4.3 (3.4-4.8) 4.5 (3.0-6.5) 4.7 (3.6-5.3) 
Lymphocytes (x109/L) - 2.1 (1.2-2.8) 2.3 (1.7-2.8) 1.8 (1.5-2.0) 
Monocytes (x109/L) - 0.5 (0.4-0.6) 0.4 (0.3-0.7) 0.6 (0.4-0.6) 
CTCL, cutaneous T-cell lymphoma; WBC, white blood cell. 
 25 
Concerning the biochemical studies (Table 4), we found that, compared to controls, the 
three groups of patients showed significantly higher levels of CRP (P=0.008, P=0.038 and 
P<0.001, for CTCL, mastocytosis and psoriasis patients, respectively). Serotonin was 
significantly increased in CTCL and mastocytosis patients (P=0.049 and P=0.005, 
respectively). E-selectin was significantly enhanced in CTCL (P=0.043), and in psoriasis 
patients (P<0.001). IL-31 levels showed a strong trend towards an increase (P=0.055) in 
CTCL patients. The levels of IL-8 (P=0.043) and VEGF (P=0.005) were significantly higher 
in psoriasis patients. 
 
Table 4 Biochemical studies for controls and patients 
 
Control  
(n=33) 
CTCL  
(n=29) 
Mastocytosis 
(n=17) 
Psoriasis  
(n=30) 
IL-8 (pg/mL) 8.7 (4.8-20.6) 10.2 (4.8-27.9) 8.0 (4.8-36.8) 
14.1 (7.9-82.4) 
* 
IL-31 (pg/mL) 9.3 (1.2-20.8) 17.3 (6.1-28.3)  6.8 (2.3-30.4) 10.7 (4.1-29.0) 
Serotonin 
(ng/mL) 
164.6 (110.7-197.8) 
182.2 (160.6-239.9) 
* 
239.5 (155.0-260.6)  
** 
140.7 (33.1-191.3) 
● ◊◊ 
E-selectin 
(ng/mL) 
38.5 (28.1-43.7) 
44.0 (31.2-84.3) 
* 
36.1 (28.5-53.7) 
56.8 (44.1-81.4) 
*** ◊◊ 
VEGF (pg/mL) 588 (472-725) 653 (429-879) 849 (440-1243) 
841 (541-1117) 
** 
CRP (µg/mL) 0.7 (0.3-0.9) 1.4 (0.5-5.5) * 
1.2 (0.4-3.9) 
* 
2.0 (0.7-4.7) 
*** 
Tryptase 
(ng/mL) 
- - 23.7 (10.1-49.3) - 
 
Tryptase levels, a marker for mast cell activation, were measured only in mastocytosis patients. 
CTCL, cutaneous T-cell lymphoma; IL, interleukin; VEGF, vascular endothelial growth factor; 
CRP, C-reactive protein. 
*P vs control <0.05; **P vs control <0.01, ***P vs control ≤ 0.001; ●P vs lymphoma <0.05; ◊◊P vs 
mastocytosis <0.01 
 
In CTCL patients, E-selectin presented a significant and positive correlation with CRP 
levels (r=0.613, P<0.001) and pruritus intensity (r=0.564, P=0.001); pruritus was also 
significantly and positively correlated with age (r=0.511, P=0.005). Moreover, CTCL patients 
with pruritus (n=18) were significantly older than non-pruritic ones (n=11) ([median (IQR)] 
70 (55-74) and 59 (51-69), respectively; P=0.040). We also observed that the levels of IL-
31 were significantly higher in CTCL patients with pruritus than in CTCL patients without 
that symptom ([median (IQR)] 25.1 (8.3-38.6) vs 10.3 (1.8-21.9), respectively; P=0.028). 
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Considering CTCL variants, we found a three-fold increase in IL-31, a two-fold increase 
in E-selectin and a five-fold increase in the levels of CRP in SS patients, as compared to 
MF patients (P=0.003, P=0.021 and P=0.029, respectively) and to control group (P=0.001, 
P=0.002,  P<0.001, respectively) (Figure 1A-C). Pruritus was also significantly more severe 
in SS compared to MF patients (P=0.001) (Figure 1D). SS patients presented significant 
and positive correlations between CRP and E-selectin (r=0.891, P=0.001) and the same 
type of correlation was observed between E-selectin and pruritus (r=0.820, P=0.004) and 
between IL-8 and VEGF (r=0.900, P<0.001).  
 
 
 
Figure 1. Differences in studied biomarkers between controls, mycosis fungoides and 
Sezary syndrome patients.  
Interleukin (IL)-31 (A), E-selectin (B) and C-reactive protein (CRP) (C) levels were assessed by 
ELISA in Mycosis Fungoides (MF; n=17) and Sezary Syndrome (SS; n=10) patients, and controls 
(n=33). The intensity of pruritus (D) was evaluated by VAS in MF and SS patients. 
*P <0.05; ***P ≤0.001. 
 
There were no statistical significant differences in studied parameters between MF 
patients and controls. However, there was a trend towards an increase in the serotonin 
levels (P=0.057). Moreover, in MF patients, IL-31 correlated significantly and positively with 
CRP (r=0.487, P=0.047).  
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In mastocytosis patients, we found a positive and significant correlation between the 
severity of pruritus and the levels of tryptase (r=0.670, P=0.009). Indeed, patients with 
pruritus (n=10) had significant higher levels of tryptase than those that did not complain of 
this symptom (n=7) ([median (IQR)] 42.6 (14.0-177.6) and 9.0 (3.4-34.0), respectively; 
P=0.020). 
In psoriasis, IL-8 correlated significantly and positively with E-selectin, VEGF and CRP 
(r=0.413, P=0.023; r=0.393, P=0.032 and r=0.443, P=0.016, respectively) (Figure 2A-C). 
  
 
Figure 2. Correlation between studied biomarkers in psoriasis patients.  
Serum levels of interleukin (IL)-8, E-selectin (A), vascular endothelial growth factor (VEGF) (B) 
and C-reactive protein (CRP) (C) were measured by ELISA in psoriasis patients (n=30). 
 
Moreover, serotonin levels showed a significant and positive correlation with IL-31 and 
VEGF (r=0.373, P=0.042 and r=0.500, P=0.005, respectively); positive and significant 
correlations were also found between CRP and the total leucocyte (r=0.597, P=0.001), 
neutrophil (r=0.680, P<0.001) and monocyte (r=0.486, P=0.016) counts, as well as with 
PASI score (r=0.556, P=0.002), in psoriasis patients.  
When psoriasis patients were divided according to severity of disease, considering PASI 
score, we found that severe psoriasis patients presented significantly higher levels of IL-8 
(P=0.019), E-selectin (P0.001), and VEGF (P=0.002), as compared to controls (Figure 
3A-C); CRP levels were also higher in severe patients as compared to controls (P<0.001) 
and to patients with moderate psoriasis (P=0.003) (Figure 3D). Moderate psoriasis patients 
presented also significantly higher levels of E-selectin, when compared to control subjects 
(P=0.004) (Figure 3B). 
We evaluated also IL-33, for all the groups studied, however, all the results were below 
the detection line. 
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Figure 3. Differences in studied biomarkers between controls and patients with moderate 
and severe psoriasis. 
 Interleukin (IL)-8 (A), E-selectin (B), vascular endothelial growth factor (VEGF) (C) and C-
reactive protein (CRP) (D) levels in moderate (n=16) and severe psoriasis patients (n=14), and 
controls (n=33). 
*P <0.05; **P <0.01; ***P ≤0.001. 
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Discussion 
The mechanisms underlying pruritus are complex and seem to involve, for different 
diseases, different pathways, cells and mediators. Figure 4 aims to illustrate the intricate 
pathways in the pathogenesis of CTCL, mastocytosis and psoriasis and its relations to 
pruritus. In the three diseases, skin damage activates antigen presenting cells, which 
release inflammatory cytokines (in particular IL-8), recruiting more circulating neutrophils 
and T-lymphocytes (1). APCs are also able to travel to the nearest lymph node (2), allowing 
expansion of antigenic-specific effector T-cells that travel through the blood stream (3) and 
enter the affected area via adhesion molecules, such as E-selectin; neutrophils are also 
capable to recruit T-lymphocytes, further increasing their homing to the skin (4). T 
lymphocytes may undergo phenotype switch, according to cytokine environment (5): Th1 
and Th17 cells, involved in the pathogenesis of psoriasis, activate macrophages and 
dendritic cells through the production of IFN, TNF and IL-17 (6), which, together with 
neutrophils, are able to activate keratinocytes (7). Activated keratinocytes produce VEGF 
and IL-8, enhancing vascularization of the tissue and recruitment of more immune cells (8).  
In CTCL, particularly, as disease evolves from MF to the more aggressive SS, a Th1 
cytokine profile switches to a Th2 cytokine profile (9). 
Th2 lymphocytes are able to modulate the metabolism of MCs, through the release of 
Th2 cytokines (IL-3 and IL-4) (10). In mastocytosis, the malignant MCs undergo clonal 
expansion, with release of mediators, including IL-8, IL-31 and VEGF. IL-8 is chemotactic 
for neutrophils and VEGF induces angiogenesis and vascularization (11).  
The pool of cytokines involved in the pathogenesis of these diseases is present not only 
in lesioned areas, but has also a systemic spread. 
Pruritus perception begins in the neuronal pathways of pruriceptive information of the 
epidermis (top left). Briefly, unmyelinated C-fibres and Aδ-fibres sense pruritic stimuli.  
Sensory input is then integrated into electrical information, conducted to dorsal root ganglion 
neurons. From the spinal cord, second-order neurons synapse with STT neurons that pass 
through the thalamus and in to the somatic sensory cortex, where information is processed. 
Pruritus is a difficult symptom to treat; indeed, different diseases, as well as different 
clinical stages of the same disease, may respond differently to the same itch treatment. Our 
results are in line with this, showing that pruritus, in CTCL, mastocytosis and psoriasis, 
involves different mediators, and, thus, it is likely that it involves different pathways and, 
therefore, different therapeutical targets should be considered. 
CTCL, mastocytosis and psoriasis are all associated with inflammation, as shown by the 
increased levels of CRP found in the patients, as compared to controls. 
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Figure 4. Pathogenesis and itch mechanisms in cutaneous T cell lymphoma, mastocytosis and psoriasis. 
 
See text for description 
APC, antigent presenting cell; CTL, cytotoxic T lymphocyte; DC, dendritic cell; DRG, dorsal rooq1t ganglion; IFN, interferon; IL, interleukin; MC, mast cell; 
mø, macrophage; nø, neutrophil; CD3+, T lymphocyte; Tmem, memory T cell; Th, T helper cell; Treg, regulatory T cell; TNF, tumour necrosis factor; STT, 
spinothalamic tract; VEGF, vascular endothelial growth factor; the squares, circles and triangles inside the blood vessel represent the systemic spread of the 
molecules involved in the pathogenesis of the three diseases.  
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In CTCL, itch is a frequent, chronic and severe symptom, interfering with patients’ QoL 
since early stages. In the present study, we found that CTCL patients presented significantly 
higher levels of E-selectin and serotonin, as compared with controls. Also, and as previously 
mentioned, several studies reported that IL-31 levels correlate with pruritus in CTCL 
patients (45, 46). We also found a significant correlation between pruritus and IL-31 in CTCL 
patients; moreover, CTCL patients with pruritus showed significantly higher levels of IL-31, 
compared with non-pruritic CTCL patients, although IL-31 blood levels were not significantly 
higher than in controls.  
IL-31 is produced by the malignant T cell clone (46) and, in mice skin, homing of T 
lymphocytes from SS patients was mediated by E-selectin (51). Our data are in accordance 
with these findings, suggesting that IL-31 and E-selectin are important players in the 
mechanisms underlying pruritus in CTCL, especially in SS. The high levels of IL-31 are 
likely to result from an overwhelming production by T cell malignant clone, and the elevated 
levels of E-selectin may contribute to the development of erythroderma, observed in SS 
patients.  
We also found, in CTCL, a significant correlation between age and itch, showing that 
elderly patients are more prone to suffer from pruritus, and, consequently, this should be 
considered when treating this symptom in old-age patients.  
CTCL includes a complex array of diseases, namely the variants MF and SS, with 
different clinical manifestations and therapeutic responses.  
MF, usually, presents as a mild and localized form of CTCL. Actually, our data showed 
that the levels of the studied biomarkers in MF patients were very similar to those of the 
control group; they presented, however, a tendency for higher levels of serotonin. Studies 
using serotonin re-uptake inhibitors showed significant improvement of pruritus in various 
diseases, including haematological malignancies (22, 132), indicating that serotonin 
agonists may be a potential solution for the treatment of this symptom. On the same note, 
the serotonin agonist mirtazapine was effective in treating itch in MF/SS patients (100). 
Thus, the increase in serotonin levels seems to be beneficial to the management of this 
symptom, but more studies are necessary to clarify its role in CTCL-associated itch.  
SS is a systemic and more aggressive form of CTCL than MF. We found that pruritus 
intensity was higher in SS patients, as compared to MF. According to our findings, IL-31, E-
selectin and CRP levels were significantly enhanced in SS patients, comparatively to MF 
patients, showing that the inflammatory process is more pronounced in SS. E-selectin 
correlated with the inflammatory marker CRP, and with pruritus intensity. Our data suggest 
an important role for E-selectin, inflammation and for IL-31 in the development of itch in 
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these patients. In fact, a study using a monoclonal antibody against IL-31 diminished 
scratching behaviour in a mouse model of atopic dermatitis (133), and Cedeno-Laurent et 
al. demonstrated that disruption of IL-31 production by malignant T lymphocytes 
successfully abolished pruritus in SS patients (45).  
Regarding E-selectin, a study measuring this adhesion molecule in the serum of CTCL 
patients with skin lesions, including MF and SS, did not find increased levels of E-selectin, 
compared to controls (134); however, the same study reported that E-selectin correlated 
positively and significantly with lactate dehydrogenase, a marker of poorer prognosis in 
CTCL, and that is increased in the more aggressive forms of the disease (135). This 
controversial data about E-selectin may result from the inclusion of MF and SS patients in 
the same study population. Actually, E-selectin values seem to reflect the severity of 
inflammation and pruritus, which is lower in MF patients. 
In summary, E-selectin and IL-31 seem to be important biomarkers underlying pruritus 
in SS patients, but less important in MF patients, in whom serotonin may play a more 
significant role in triggering itch.  
Mastocytosis is characterized by high levels of MCs, both in circulation and disseminated 
through body organs. In this study, in agreement with others (136), mastocytosis patients 
presented higher levels of serotonin, although, as Kushnir-Sukhov et al. demonstrated (21), 
no significant correlation was found between serotonin values and pruritus. 
The pruritic effect of tryptase was already demonstrated in mice (137), and in itch of 
atopic dermatitis patients (138). Accordingly, we found in mastocytosis patients a positive 
correlation between pruritus and tryptase levels. Tryptase is a marker of MC burden and 
activation, and this correlation suggests that pruritus is linked to MC-mediator release. 
Strengthening this linkage, we found significantly higher levels of tryptase in mastocytosis 
patients with pruritus, as compared with patients who did not present that symptom. 
However, when patients were divided according to levels of tryptase ( and  20 ng/mL), 
we did not find a significant difference in pruritus intensity between the two groups. This 
may result from the low number of patients in each group. More studies are needed to clarify 
the mediators and pathways implied in pruritus in mastocytosis. 
Psoriasis is a chronic and inflammatory skin disease, in which itch is a common skin 
manifestation. In psoriasis patients, we measured skin manifestations using the first 
question of the DLQI questionnaire (Annex 1), asking “Over the last week, how itchy, sore, 
painful or stinging has your skin been?”. As this is a less accurate evaluation of pruritus 
than VAS, it may explain why we did not find a correlation between itch and the significantly 
elevated levels of E-selectin, as was previously reported in psoriasis (32), and with the 
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levels of VEGF, in prurigo simplex, an inflammatory skin condition that presents with intense 
itch (55). Moreover, no significant correlations were observed between the pruritus score 
and the other biomarkers studied, suggesting that they may not be related to itch 
mechanism in psoriasis. Actually, further studies, evaluating pruritus with a more accurate 
tool, are necessary to clarify the value of those biomarkers in the genesis of itch in psoriasis. 
The levels of IL-8, E-selectin, VEGF and CRP were found to be elevated in this condition, 
which translate the clinical manifestations and histology of psoriasis. Indeed, the elevated 
levels of IL-8, a chemoattractant for neutrophils, and E-selectin, an adhesion molecule, 
explain the neutrophilic infiltrate common in psoriatic lesions histology. The high values of 
VEGF account for the intense local angiogenesis/vascularization, which confers a reddish 
colour to the cutaneous lesions. Serum E-selectin was also previously demonstrated to be 
increased in psoriasis patients and to be correlated with PASI score (139), and, although 
we did not find that correlation, we found statistically significant differences in E-selectin 
levels between patients with moderate and severe disease, and the control group. 
Nakamura et al. (32) also reported a two-fold increase in this endothelial adhesion molecule 
in psoriatic skin with pruritus, compared to non-pruritic lesioned skin, which further 
strengthens the need for clarification of the relationship between pruritus and this and other 
biomarkers. Our group has already reported, in a previous work, that IL-8 and VEGF levels 
are elevated in psoriasis patients (35), as well as CRP values. Indeed, we proposed this 
acute phase protein as a possible biomarker of psoriasis severity (140), in agreement with 
the results of the present study.  
In opposition to Narbutt et al. (84), but in accordance with Czarnecka-Operacz et al. 
(141) studies, we did not find a role for IL-31 in itch in psoriasis. The existence of higher 
levels of IL-31 and serotonin in CTCL and mastocytosis patients, as compared to controls, 
but not in psoriasis patients, may be related to the type of immune response. Psoriasis 
presents a Th1/17 immune response (66), whereas in the early stages of CTCL there is a 
dominance of the Th1 profile, and in advanced stages occurs a switch to a Th2 profile; in 
mastocytosis, the Th2 pathway seems to have an important role (46, 116).  
In summary, our data suggests that serotonin and tryptase are important biomarkers in 
mastocytosis, but further studies are needed to identify itch-mechanisms in this condition. 
The high levels of IL-8, E-selectin, VEGF and CRP in psoriasis, especially of E-selectin and 
CRP in the severer forms of the disease, suggest that they are are potential biomarkers of 
psoriasis severity, and further studies are needed to clarify their involvement in itch 
mechanisms. In CTCL patients with the more aggressive form, SS, E-selectin and IL-31 
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appear to be important in itchy pathways, while in MF patients, the increase in serotonin 
seems to be more important in the mechanisms underlying pruritus. 
Our data strengthens the hypothesis that different mechanisms underlie the genesis of 
itch in these diseases, explaining the different therapeutic responses to common 
treatments, and proposes some potential therapeutic targets for the treatment of itch in 
CTCL, mastocytosis and psoriasis patients.  
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